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WORLDWIDE, THE PREVA-lence of type 2 diabetesis very high and increas-ing. The World Health
Organization (WHO) predicts that be-
tween 1995 and 2025, the worldwide
prevalence of diabetes among persons
aged 20 years and older will increase
from 4.0% to 5.4%.1 Diabetes is asso-
ciated with a high risk for microvascu-
lar and macrovascular complications
and with a high risk of premature
death.2-4
For prevention purposes, there is great
interest in the identification of persons
at high risk for developing diabetes.
Therefore, several follow-up studies have
been performed in nonwhite popula-
tions with a high prevalence of diabe-
tes5-7 and among persons with impaired
glucose tolerance (IGT).8-10 Edelstein et
al11 reported cumulative incidences rang-
ing from 23% to 62% in 6 prospective
studies among persons with IGT, within
2 to 27 years of follow-up. The inci-
dence was higher among the Hispanic,
Mexican-American, Pima, and Nau-
ruan populations compared with the in-
cidence among white populations. Vari-
ables predictive of the development of
diabetes in different studies were fast-
ing and postload glucose,7,11-13 obe-
sity,11,12 and such lifestyle variables as
physical inactivity.14
However, little is known about the
conversion from normal glucose toler-
ance (NGT) to diabetes in white per-
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Context Persons with impaired glucose tolerance (IGT) are known to have an el-
evated risk of developing diabetes mellitus. Less is known about diabetes risk among
persons with impaired fasting glucose (IFG) or with normal glucose levels.
Objective To determine the incidence of diabetes in relation to baseline fasting and
postload glucose levels and other risk factors.
Design, Setting, and Participants Population-based cohort study conducted from
October 1989 to February 1992 among 1342 nondiabetic white residents of Hoorn,
the Netherlands, aged 50 to 75 years at baseline, in whom fasting plasma glucose (FPG)
levels and glucose levels 2 hours after a 75-g oral glucose tolerance test were mea-
sured at baseline and at follow-up in 1996-1998.
Main Outcome Measures Cumulative incidence of diabetes, defined according
to the diagnostic criteria of the World Health Organization (WHO-1985 and WHO-
1999) and the American Diabetes Association (ADA-1997), during a mean follow-up
of 6.4 years, compared among participants with IFG, IGT, and normal glucose levels
at baseline.
Results The cumulative incidence of diabetes was 6.1%, 8.3%, and 9.9% according
to the WHO-1985, ADA, and WHO-1999 criteria, respectively. The cumulative inci-
dence of diabetes (WHO-1999 criteria) for participants with both IFG and IGT was 64.5%
compared with 4.5% for those with normal glucose levels at baseline. The odds ratios
for diabetes (WHO-1999 criteria), adjusted for age, sex, and follow-up duration, were
10.0 (95% confidence interval [CI], 6.1-16.5), 10.9 (95% CI, 6.0-19.9), and 39.5 (95%
CI, 17.0-92.1), respectively, for those having isolated IFG, isolated IGT, and both IFG
and IGT. In addition to FPG and 2-hour postload glucose levels (P,.001 for both), the
waist-hip ratio also was an important risk factor for developing diabetes (P=.002).
Conclusion In this study, the cumulative incidence of diabetes was strongly related
to both IFG and IGT at baseline and, in particular, to the combined presence of IFG
and IGT.
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sons. Furthermore, even less is known
about the incidence of diabetes among
persons with impaired fasting glucose
(IFG) and normal fasting glucose
(NFG)—relatively new categories de-
fined by the American Diabetes Associa-
tion (ADA) in 1997.15 Because the ADA
criteria are based on fasting plasma glu-
cose (FPG) values only, and because the
cutoff point for the diagnosis of diabe-
tes has been lowered to 126 mg/dL (7.0
mmol/L) (the cutoff point of the WHO-
1985 criteria is 140 mg/dL [7.8 mmol/
L]),16 it is of importance to know how
this affects the incidence of diabetes. This
lower cutoff point for FPG was adopted
by the WHO in 1999. The WHO-1999
criteria differ from the ADA criteria by
still taking into account the postload glu-
cose levels.17
Therefore, in the present study we in-
vestigated the cumulative incidence of
diabetes in the white population of the
Hoorn Study, which has been fol-
lowed up for 6 years. We compared the
incidence of diabetes among partici-
pants having normal glucose levels,
IFG, IGT, or both IFG and IGT at base-
line according to the WHO-1985, ADA,
and WHO-1999 diagnostic criteria. We
also determined which other variables
were predictive of the development of
diabetes.
METHODS
Study Population
The Hoorn Study, begun in 1989, is a
population-based cohort study on glu-
cose intolerance in a general Dutch el-
derly population. The study popula-
tion and design have been described in
detail previously.18 In summary, a ran-
dom sample (n=3553) of all inhabit-
ants of Hoorn aged 50 to 75 years was
invited to take part in the study. A total
of 2540 subjects (71%) agreed to par-
ticipate. After exclusion of 56 non-
white participants, the study cohort con-
sisted of 2484 men and women. The
baseline examination took place be-
tween October 1989 and February 1992.
Between January 1996 and Decem-
ber 1998, a follow-up examination was
carried out. Of the initial cohort, 150
persons had died and 108 had moved
out of Hoorn before 1996. One hun-
dred forty other persons were not in-
vited because of logistic reasons. Of the
remaining 2086 persons who were in-
vited for the follow-up examination,
1513 (72.5%) participated. In the pres-
ent study all analyses have been done
on 1342 participants, because those
who had diabetes according to any one
of the diagnostic criteria at baseline or
who had missing values for glucose
were excluded (FIGURE).
All participants gave their written in-
formed consent for participation in the
Hoorn Study. The Ethics Committee of
the University Hospital Vrije Univer-
siteit Amsterdam approved the design
of the study.
Glucose Measurements
For the measurement of FPG, a blood
sample was taken after an overnight fast.
Subsequently, a 75-g oral glucose tol-
erance test (OGTT) was administered
and the plasma glucose level was mea-
sured 2 hours later (2hPG). The glu-
cose levels were determined by a glu-
cose dehydrogenase method (Merck,
Darmstad, Germany).
At both baseline and follow-up, all
participants were classified in catego-
ries of glucose intolerance. In the WHO-
1985 criteria, diabetes is diagnosed if
FPG is 140 mg/dL (7.8 mmol/L) or
greater or if 2hPG is 200 mg/dL (11.1
mmol/L) or greater,16 while by the ADA
criteria, an FPG of 126 (7.0 mmol/L)
or greater is sufficient.15 In the WHO-
1999 criteria, these are combined and
therefore diabetes is defined by an FPG
level of 126 mg/dL (7.0 mmol/L) or
greater or a 2hPG level of 200 mg/dL
(11.1 mmol/L) or greater.17 Partici-
pants who were already treated for dia-
betes by insulin, hypoglycemic agents,
or a physician-prescribed diet were cat-
egorized as persons with known dia-
betes, irrespective of their glucose lev-
els. In case of doubt the medical
information in the hospital or at the
general practitioner was checked. In all
analyses, known and newly diagnosed
diabetes was taken together.
Impaired fasting glucose is defined as
an FPG between 110 mg/dL (6.1
mmol /L) and 126 mg/dL (7 .0
mmol/L).15 By WHO-1985 criteria, IGT
is diagnosed if FPG is less than 140
mg/dL (7.8 mmol/L) and 2hPG is be-
tween 140 mg/dL (7.8 mmol/L) and 200
mg/dL (11.1 mmol/L).16
Other Measurements
Weight and height were measured with
participants wearing light clothing only,
and the body mass index (BMI) was cal-
culated as weight divided by the square
of the height (kg/m2). Waist and hip cir-
cumferences were measured and the
waist-hip ratio (WHR) was defined as
waist circumference divided by hip cir-
cumference.
Blood pressure was measured twice
on the right arm while sitting and with
a random-zero sphygmomanometer
(Hawksley-Gelman, Lancing, England).
The average of these 2 measurements
was used for analyses. Participants were
considered hypertensive if their sys-
Figure. Study Population at the Baseline and
at Follow-up Examination
3553  Adults Aged 50 to 75 Years
          Invited to Participate
2484  Participated in Baseline Examination
          (Between 10/1989 and 2/1992)
1069  Excluded
          1013  Declined to Participate
              56  Nonwhite
1513  Participated in Follow-up Examination
          (Between 1/1996 and 12/1998)
1342  in Study Population
2086  Invited to Participate in Follow-up
          Examination
171  Excluded
        136  Had Diabetes at Baseline
          35  Had Missing Values
  398  Excluded
          150  Died
          108  Moved
          140  Logistic Reasons
  573  Declined to Participate 
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tolic blood pressure was 160 mm Hg or
greater, their diastolic blood pressure
was 95 mm Hg or greater, or if they
were using antihypertensive medica-
tion. Information on smoking habits
(yes or no) and participation in sports
(hours per week) was obtained by ques-
tionnaire.18
Statistical Methods
All statistical analyses were done with
SPSS 9.0.19 All P values were based on
2-sided tests, and the cutoff for statis-
tical significance was .05.
The cumulative incidence of diabetes
was calculated as the number of partici-
pants who developed diabetes during the
follow-up divided by the total number
of those at risk at baseline. We com-
pared the 6-year cumulative incidence of
diabetes between the WHO-1985, the
ADA, and the WHO-1999 diagnostic cri-
teria. Furthermore, we compared the cu-
mulative incidences for combinations of
normal, impaired fasting, and impaired
postload glucose levels.
The follow-up duration was calcu-
lated as the time between the baseline
and the follow-up measurements, and
the incidence densities were calcu-
lated. Because the mean follow-up du-
ration was not equal in the categories
of glucose intolerance, logistic regres-
sion adjusting for follow-up duration
was used to estimate odds ratios (ORs)
and 95% confidence intervals (CIs). The
ORs were also adjusted for age and sex.
The Hosmer-Lemeshow goodness-of-
fit test was used to assess the overall fit
of the logistic regression model.20
The OR is the ratio of the odds of 2
categories and can be interpreted as an
approximation of the relative risk. In
this study, odds represent the chance
for conversion to diabetes relative to the
chance for nonconversion to diabetes
in 1 particular category. The ORs will
overestimate the relative risk when the
disease under study is not rare.21
To investigate which other vari-
ables were predictive of the develop-
ment of diabetes, the variables WHR
(3100), BMI, hypertension, smoking,
and participation in sports were added
1 by 1 into a logistic regression model
including also FPG, 2hPG, age, sex, and
follow-up duration as independent vari-
ables. Finally, all statistically signifi-
cant variables were included together
into 1 logistic regression model.
RESULTS
The study population consisted of 610
men and 732 women with a mean age
of 60.3 (SD, 6.9) years at baseline, who
were followed up for 6.4 years (range,
4.4-8.1 years).
As a consequence of the definitions
used, the cumulative incidence of dia-
betes was highest according to the
WHO-1999 criteria: 9.9% compared
with 6.1% and 8.3% according to the
WHO-1985 and the ADA criteria, re-
spectively. Of the 1231 participants with
NGT at baseline, 46 (3.7%) had diabe-
tes at follow-up according to the WHO-
1985 criteria. For participants with IGT
the cumulative incidence was 32.4%
(WHO-1985 criteria). According to the
ADA criteria, the cumulative incidence
was 5.0% for participants with NFG and
38.0% for those with IFG (TABLE 1).
The cumulative incidence (WHO-
1999 criteria) among participants with
both impaired fasting and impaired
postload glucose levels was 64.5%, com-
pared with 4.5% for those with both
normal fasting and normal postload glu-
cose levels. Among participants with
isolated IFG or IGT, the cumulative in-
cidence of diabetes was similar (33.0%
and 33.8%, respectively). However, the
mean follow-up durations were not
equal in these categories. The ORs ad-
justed for follow-up duration, age, and
sex were 10.0 and 10.9 for isolated IFG
and IGT, respectively. The OR for par-
ticipants with both IFG and IGT rela-
tive to those with normal glucose lev-
els was very high (39.5 [95% CI, 17.0-
92.1]) (TABLE 2).
When the analyses were stratified for
men and women, we observed a slightly
higher cumulative incidence of diabe-
tes in men than in women (10.5% vs
9.4%, respectively; WHO-1999 criteria).
For participants with the combined
presence of IFG and IGT the cumula-
tive incidence was more pronounced in
women (75.0%) than in men (53.3%).
In addition to fasting and postload glu-
cose levels, which were the 2 most im-
portant predictors for progression to dia-
betes (both P,.001), the WHR also was
highly predictive of incident diabetes
(P=.002). Of less importance, and not
statistically significant, were smoking,
hypertension, participation in sports, and
BMI. Including the statistically signifi-
cant variables into 1 model, the OR ex-
pressed per 1-SD difference was 2.32
(95% CI, 1.85-2.90) for FPG, 1.97 (95%
CI, 1.59-2.44) for 2hPG, and 1.57 (95%
CI, 1.19-2.08) for the WHR (TABLE 3).
COMMENT
In this prospective cohort study of a
white population, 64.5% of the partici-
pants who had both impaired fasting
Table 1. Six-Year Cumulative Incidence of Diabetes According to WHO-1985 and ADA
Diagnostic Criteria*
Baseline Category
Cutoff Values,
FPG/2hPG, mg/dL No.
Diabetes at
Follow-up, No.
(%)‡
WHO-1985
NGT ,126/,140† 1231 46 (3.7)
IGT ,126/140-200† 111 36 (32.4)
Total 1342 82 (6.1)
ADA
NFG ,110§ 1205 60 (5.0)
IFG 110-126§ 137 52 (38.0)
Total 1342 112 (8.3)
*WHO indicates World Health Organization; ADA, American Diabetes Association; FPG, fasting plasma glucose; 2hPG,
2-hour postload glucose; NGT, normal glucose tolerance; IGT, impaired glucose tolerance; NFG, normal fasting glu-
cose; IFG, impaired fasting glucose. To convert mg/dL to mmol/L, multiply mg/dL by 0.05551.
†Cutoff level for FPG is 126 mg/dL, because all analyses were carried out in the 1342 subjects who did not have dia-
betes according to any of the diagnostic criteria at baseline.
‡Cutoff values for WHO-1985 are FPG $140 mg/dL or 2hPG $200 mg/dL; for ADA, FPG $126 mg/dL.
§Cutoff levels for FPG only.
DIABETES AND IMPAIRED GLUCOSE
©2001 American Medical Association. All rights reserved. (Reprinted) JAMA, April 25, 2001—Vol 285, No. 16 2111
 at Vrije Universiteit on August 19, 2011jama.ama-assn.orgDownloaded from 
and impaired postload glucose levels at
baseline progressed to diabetes (WHO-
1999 criteria) during the 6-year follow-
up. Of those with normal fasting and
postload glucose levels at baseline, 4.5%
had diabetes at the follow-up exami-
nation. To our knowledge, this is the
first large prospective study among
whites that reports on the cumulative
incidence of type 2 diabetes according
to WHO-1985, ADA, and WHO-1999
diagnostic criteria.
The baseline cohort (n=2484) of the
Hoorn Study was a random sample of
the population of the municipality of
Hoorn, aged 50 to 75 years. The pres-
ent analyses have been done in 1342 par-
ticipants who did not have diabetes ac-
cording to any 1 of the diagnostic criteria
at baseline and who did not have miss-
ing values for glucose. Of the 2086 per-
sons who were invited for the fol-
low-up examination, 1513 participated
and 573 did not. As is frequently ob-
served in population studies, the par-
ticipants were more healthy. The par-
ticipants were younger (60.6 vs 63.2
years), less hypertensive (28.2% vs
34.8%), had a lower WHR (0.89 vs 0.90),
and a more favorable lipid profile at base-
line. Furthermore, they had lower mean
baseline FPG levels (101.8 mg/dL [5.65
mmol/L] vs 105.5 mg/dL [5.85 mmol/
L]), lower 2hPG levels (106.5 mg/dL
[5.981 mmol/L] vs 112.2 mg/dL [6.23
mmol/L]), and lower glycosylated he-
moglobin values (5.4% vs 5.6%). There-
fore, we may have underestimated the
true cumulative incidence of diabetes in
the general population.
Because of ongoing follow-up stud-
ies, persons with IGT were first in-
vited for the follow-up measure-
ments. This resulted in an unequal
distribution over the categories for the
mean follow-up duration, with per-
sons with the highest risks for progres-
sion to diabetes having the shortest fol-
low-up duration. In a logistic regression
model we therefore adjusted for fol-
low-up duration.
The glucose levels were determined
only once at baseline and at follow-
up. Because of the known high intra-
individual variation in glucose levels,
especially for postload glucose, some
misclassification might have occurred
when participants were categorized into
glucose tolerance categories.22,23 How-
ever, we previously reported that the re-
producibility of the classification in glu-
cose tolerance categories by WHO-
1985 and ADA for 1109 persons with
duplicate OGTTs within 6 weeks was
very similar, with k values of 0.59 and
0.61, respectively, which represent fair-
to-good reproducibility.24
The incidence of diabetes was high-
est according to the WHO-1999 com-
bined criteria and the lowest inci-
dence was observed if using the WHO-
1985 criteria, which is due to the higher
cutoff level for FPG. However, the true
incidence according to the WHO-
1985 was slightly underestimated, be-
cause participants with FPG levels be-
tween 126 mg/dL (7.0 mmol/L) and 140
mg/dL (7.8 mmol/L) at baseline were
excluded in the analyses. If these par-
ticipants (n=23) were included, the cu-
mulative incidence of diabetes accord-
ing to WHO-1985 criteria was 6.9%
instead of 6.1%. For participants with
IGT and NGT the incidences then were
35.5% and 4.1%, respectively. When
only the ADA diagnostic criteria should
have been used, the analyses could have
been done in 1391 participants in-
stead of 1342. Then the cumulative in-
cidence of diabetes was 5.5% for par-
ticipants with NFG and 40.8% for those
with IFG, which is quite similar to the
values in Table 1.
Previous studies on the incidence of
diabetes were mainly performed in per-
sons with IGT only, or in nonwhite
populations with a high risk for diabe-
tes, using the WHO-1985 diagnostic cri-
teria. In South African persons, the in-
cidence of diabetes was 50.4% within
4 years7 and for Pima Indians the cu-
mulative incidence of diabetes was 62%
within 7 years.11 In Kinmen, a series of
islands located in the Pacific Ocean, the
cumulative incidence was 8.8% per
year.12 We previously reported on the
2-year cumulative incidence of diabe-
tes in a subsample of participants with
IGT in the Hoorn Study. The cumula-
tive incidence of diabetes was 28.5%
when using the mean of duplicate
OGTTs for the classification in glu-
cose tolerance categories.25
Less is known about the cumulative
incidence of diabetes of persons with
Table 2. Cumulative Incidence of Diabetes (WHO-1999 Criteria) for Combinations of Impaired Fasting and Impaired Postload Glucose Levels*
Category No.
Cutoff Values,
FPG/2hPG, mg/dL
Cumulative
Incidence, No. (%)
Mean Follow-up
Duration†
Incidence Density
(No./1000 Person-years) OR (95% CI)‡
Normal 1125 ,110/140 51 (4.5) 6.47 7.0 1.0
IFG and NGT 106 110-126/,140 35 (33.0) 6.42 51.4 10.0 (6.1-16.5)
NFG and IGT 80 ,110/140-200 27 (33.8) 5.83 57.9 10.9 (6.0-19.9)
IFG and IGT 31 110-126/140-200 20 (64.5) 5.75 112.2 39.5 (17.0-92.1)
*OR indicates odds ratio; CI, confidence interval. For expansion of other terms, see Table 1 footnote. To convert mg/dL to mmol/L, multiply mg/dL by 0.05551.
†Years between baseline and follow-up measurements.
‡Calculated by logistic regression adjusted for follow-up duration, age, and sex.
Table 3. Variables Predictive of the Development of Diabetes During 6 Years of Follow-up,
Adjusted for Age, Sex, and Follow-up Duration*
Variable
SD
(n = 1342)
OR (95% CI),
per SD Difference P Value
FPG, mg/dL 9.36 2.32 (1.85-2.90) ,.001
2hPG, mg/dL 29.33 1.97 (1.59-2.44) ,.001
WHR 3 100 8.46 1.57 (1.19-2.08) .002
*OR indicates odds ratio; CI, confidence interval; FPG, fasting plasma glucose; 2hPG, 2-hour postload glucose; and
WHR, waist-hip ratio.
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IFG. In the present study, we ob-
served a 6-year incidence of 38%. Din-
neen et al13 observed a cumulative in-
cidence of 39% within 9 years of
follow-up among Olmsted County resi-
dents aged 40 years or older with base-
line IFG. In a prospective study in Mau-
ritius among persons aged 25 to 74
years, 28.9% of the participants with
baseline IFG progressed to diabetes in
5 years, compared with 24.4% with
IGT.26 In a study in Italy among 1245
whites who were followed up for 11.5
years, participants with both IFG and
IGT at baseline had an OR of 10.3 for
developing diabetes relative to those
with both NFG and NGT. The cumu-
lative incidence of diabetes among par-
ticipants with IGT only was higher than
the cumulative incidence for subjects
with IFG only (32.5% and 9.1%,
respectively).27 These results are there-
fore only partly in line with the results
of the present study: we observed a 14-
fold higher risk for diabetes in sub-
jects with both IFG and IGT, while the
risks of the IFG-only and IGT-only cat-
egories were similar. However, the par-
ticipants in the Italian study were
younger (40-59 years) and the num-
ber of those who progressed to diabe-
tes was in some categories quite small.27
Impaired fasting glucose and IGT rep-
resent different physiologic abnormali-
ties. The primary cause for fasting hy-
perglycemia is the elevated rate of basal
hepatic glucose production in the pres-
ence of hyperinsulinemia, while IGT is
characterized by defects in both insu-
lin secretion and insulin sensitivity.28,29
Therefore, as demonstrated herein, when
there is a combined presence of these
disorders the risk for future diabetes is
very high. Furthermore, we observed
that the WHR, not the BMI, was an im-
portant predictor for progression to dia-
betes. Edelstein et al11 also observed in
4 prospective studies that the WHR was
consistently associated with the devel-
opment of diabetes. The association be-
tween BMI and incident diabetes dif-
fered between the studies reported.
Therefore, the body fat distribution may
be a better predictor for progression to
diabetes than the BMI.
In this study, the highest cumula-
tive incidence of diabetes was ob-
served for participants with both IFG
and IGT at baseline. Therefore, we con-
clude that the cumulative incidence of
diabetes among white persons aged 50
to 75 years is strongly related to both
impaired fasting and impaired post-
load glucose levels at baseline.
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